Novo Nordisk Grabs Shark Antibody-Based CNS Delivery Technology From Ossianix

 
• By John Davis

Being able to move therapeutic molecules for diabetes and other metabolic diseases into the CNS is the aim of a research collaboration and option agreement between Novo Nordisk and the six-year-old US biotech, Ossianix.

Trojan horse
The technology is a "Trojan Horse" approach to CNS drug delivery. • Source: Shutterstock

More from Deals

More from Business